皇冠登录wellcome

永利皇冠app

永利皇冠app

Our leadership, which includes our Board of Directors and Senior Executive Team, is accountable to our shareholders for the responsible conduct of the business and our long-term success. It also represents the interests of all our stakeholders in ensuring that we deliver for patients by putting science at the heart of everything we do.

永利皇冠app

永利皇冠app

Our Directors are collectively responsible for the success of AstraZeneca. In addition, the Non-Executive Directors are responsible for exercising independent and objective judgement and for scrutinising and challenging management. The Board is responsible for setting our strategy and policies, oversight of risk and corporate governance and monitoring progress towards meeting our annual plans. It is accountable to our shareholders for the proper conduct of the business and our long-term success and represents the interests of all stakeholders. The Board has delegated some of its powers to four principal committees and the CEO. Members of the Board and their biographies are shown below.

皇冠注册平台

Leif Johansson Non-Executive Chairman of the Board 永利皇冠app

Member of the Board since April 2012 and Chairman since June 2012.

Read biography
皇冠登录wellcome

Pascal Soriot Executive Director and Chief Executive Officer 永利皇冠app

Member of the Board and CEO since October 2012.

Read biography
皇冠官网平台

Marc Dunoyer Executive Director and Chief Financial Officer 永利皇冠app

Member of the Board and CFO since November 2013.

Read biography

   

永利皇冠app

永利皇冠app

In addition to the Board of Directors, our Senior Executive Team, or SET, is the body through which our Chief Executive Officer (CEO) exercises the authority delegated to him by the Board. Our CEO leads the SET and has executive responsibility for the management, development and performance of the business. The Chief Executive Officer, Chief Financial Officer and SET also take the lead in developing our strategy for review, constructive challenge and approval by the Board as part of our annual strategy review process.

永利皇冠463com

Pascal Soriot Executive Director and CEO 永利皇冠app

Read biography
永利皇冠

Marc Dunoyer Executive Director and CFO 永利皇冠app

Read biography
皇冠官网手机地址

Katarina Ageborg Executive Vice-President, Sustainability and Chief Compliance Officer; President AstraZeneca AB, Sweden 永利皇冠app

Read biography
皇冠登录网址

José Baselga Executive Vice-President, Oncology R&D 永利皇冠app

Read biography
皇冠登录网址2

Pam Cheng Executive Vice-President, Operations and Information Technology 永利皇冠app

Read biography
永利皇冠

Fiona Cicconi Executive Vice-President, Human Resources 永利皇冠app

Read biography
皇冠官网软件

Ruud Dobber Executive Vice-President, BioPharmaceuticals Business Unit 永利皇冠app

Read biography
皇冠登录网址

David Fredrickson Executive Vice-President, Oncology Business Unit 永利皇冠app

Read biography
皇冠官网入口

Menelas (Mene) Pangalos Executive Vice-President, BioPharmaceuticals R&D 永利皇冠app

Read biography
皇冠登录平台

Jeff Pott General Counsel 永利皇冠app

Read biography
皇冠官网入口

Iskra Reic Executive Vice-President, Europe and Canada 永利皇冠app

Read biography
皇冠官网手机版

Leon Wang Executive Vice-President, International 永利皇冠app

Read biography